PAOG Targets September 2021 to Introduce CBD Nutraceuticals to Market Co-Packed by ALKM and Marketed Through USMJ

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Sandusky, Ohio--(Newsfile Corp. - March 16, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today released details on the Company's nutraceutical developments initiative following last week's introduction of adding CBD RELAX-RX to existing CBD RespRx developments. The details today are highlighted by the Company's September 2021 go-to-market target date with nutraceutical co-packing to be conducted by Alkame Holdings, Inc. (OTC Pink: ALKM) and product marketing to be conducted by North American Cannabis Holdings, Inc. (OTC Pink: USMJ).

PAOG is building a comprehensive CBD nutraceuticals strategy to enhance its long-term CBD pharmaceutical strategy. Management recognizes the long-term, investment and research intensive nature of developing a pharmaceutical product and has added the nutraceutical strategy to accelerate the Company's opportunity to achieve revenue starting in 2021.

Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT".

PAOG anticipates soon announcing new breakthroughs in its CBD RespRx pharmaceutical research.

PAOG is on track to introduce its first two CBD nutraceutical products in September of this year, 2021. One CBD nutraceutical product will target the COPD market and the second will target the anxiety and depression market.

In addition to PAOG's ongoing CBD nutraceutical technical developments in Puerto Rico, PAOG expects to soon announce an additional research partnership to accelerate and expand its CBD developments initiative.

PAOG is working closely with ALKM and USMJ to package and market its first two CBD nutraceutical products and anticipates a number of announcements between now and September to introduce packaging and marketing progress and prepare the market for the September product launch.

Learn more about PAOG at www.paogroupinc.com.

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT INFORMATION

Contact Us:
Jim DiPrima
888-272-6472
[email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/77426

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).